IM Cannabis (IMCC) Other Non-Current Liabilities (2023 - 2024)
IM Cannabis (IMCC) recorded quarterly Other Non-Current Liabilities of $1.5 million in Q1 2024, down 26.31% quarter-over-quarter from $2.0 million in Q4 2023.
IM Cannabis (IMCC) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
IM Cannabis' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.5 million for Q1 2024.
- In Q1 2024, Other Non-Current Liabilities changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2024 stood at $1.5 million (changed N/A YoY), while the FY2023 annual figure was $2.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities was $1.5 million for Q1 2024 at IM Cannabis, down from $2.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.0 million in Q4 2023 to a low of $1.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | IM Cannabis | 57,090.22 | -728,264.31 | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | 1.98 Mn |